Cooley advised ERYTECH Pharma on its $143.7 million global offering of an aggregate of 6,180,137 ordinary shares, including the full exercise of the underwriters’ option to…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
